KA vs. TBIO, EDSA, GDTC, BFRG, PPBT, ITRM, INDP, JAGX, CPIX, and VINC
Should you be buying Kineta stock or one of its competitors? The main competitors of Kineta include Telesis Bio (TBIO), Edesa Biotech (EDSA), CytoMed Therapeutics (GDTC), Bullfrog AI (BFRG), Purple Biotech (PPBT), Iterum Therapeutics (ITRM), Indaptus Therapeutics (INDP), Jaguar Health (JAGX), Cumberland Pharmaceuticals (CPIX), and Vincerx Pharma (VINC). These companies are all part of the "medical" sector.
Telesis Bio (NASDAQ:TBIO) and Kineta (NASDAQ:KA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.
Telesis Bio received 6 more outperform votes than Kineta when rated by MarketBeat users. However, 100.00% of users gave Kineta an outperform vote while only 52.94% of users gave Telesis Bio an outperform vote.
Kineta has a consensus target price of $8.00, suggesting a potential upside of 1,621.54%. Given Telesis Bio's higher possible upside, analysts clearly believe Kineta is more favorable than Telesis Bio.
37.6% of Telesis Bio shares are held by institutional investors. Comparatively, 30.3% of Kineta shares are held by institutional investors. 24.5% of Telesis Bio shares are held by insiders. Comparatively, 23.7% of Kineta shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
In the previous week, Telesis Bio and Telesis Bio both had 2 articles in the media. Telesis Bio's average media sentiment score of 1.43 beat Kineta's score of 0.43 indicating that Kineta is being referred to more favorably in the news media.
Kineta has a net margin of 0.00% compared to Kineta's net margin of -183.66%. Kineta's return on equity of -359.32% beat Telesis Bio's return on equity.
Telesis Bio has a beta of 1.93, suggesting that its share price is 93% more volatile than the S&P 500. Comparatively, Kineta has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500.
Kineta has lower revenue, but higher earnings than Telesis Bio. Kineta is trading at a lower price-to-earnings ratio than Telesis Bio, indicating that it is currently the more affordable of the two stocks.
Summary
Telesis Bio and Kineta tied by winning 8 of the 16 factors compared between the two stocks.
Get Kineta News Delivered to You Automatically
Sign up to receive the latest news and ratings for KA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
